Informuta
Informuta is at the forefront of precision medicine, focusing on combating antibiotic resistance through AI and DNA sequencing. Their proprietary technology, RESISENSE, predicts bacterial responses to antibiotics, enabling targeted treatment and improving patient outcomes. With a mission to revolutionize infectious disease detection, Informuta aims to conserve current antibiotics and enhance treatment efficacy. They are preparing for a multi-center clinical trial set to begin in November 2024, with a product launch anticipated in late 2026, positioning themselves as leaders in the diagnostic market for drug-resistant infections.
Informuta
Informuta is at the forefront of precision medicine, focusing on combating antibiotic resistance through AI and DNA sequencing. Their proprietary technology, RESISENSE, predicts bacterial responses to antibiotics, enabling targeted treatment and improving patient outcomes. With a mission to revolutionize infectious disease detection, Informuta aims to conserve current antibiotics and enhance treatment efficacy. They are preparing for a multi-center clinical trial set to begin in November 2024, with a product launch anticipated in late 2026, positioning themselves as leaders in the diagnostic market for drug-resistant infections.
TL;DR
What they do: AI/ML + NGS diagnostic (RESISENSE) that predicts existing and treatment‑emergent antibiotic resistance
Founded: 2023
Location / base: San Diego
Clinical progress: Clinical validation and prospective/multi-center studies underway; clinical lab opened in New Orleans
Funding signal: Pre‑seed funding including America's Seed Fund (NSF) and Boot64 Ventures; total disclosed funding $1,300,000 (USD)
Company Overview
Problem Domain
Antibiotic resistance diagnostics and precision infectious‑disease treatment
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
Pre‑seed investment recorded on Sep 13, 2024
1300000
Most recent funding date listed as 2025-03-26; total funding amount reported as 1,300,000 USD
Boot64 Ventures listed as an investor
Investor Signal
“Includes America's Seed Fund (National Science Foundation) and Boot64 Ventures; local investor coalition referenced for New Orleans lab expansion”